Frontiers of Medicine最新文献_第9页

A pilot study on Paxlovid therapy for hemodialysis patients with severe acute respiratory syndrome coronavirus 2 infections. Paxlovid治疗重症急性呼吸综合征冠状病毒2型感染血液透析患者的初步研究

IF 8.1 3区医学

Frontiers of Medicine Pub Date : 2024-02-01 Epub Date: 2023-11-18 DOI: 10.1007/s11684-023-1011-0

Xu Hao, Zhiyao Bao, Ranran Dai, Xiaojing Wu, Xin Li, Muyin Zhang, Hao Li, Lili Xu, Panpan Qiao, Xuefei Liu, Weiting Hu, Ze Zhang, Jie Fang, Min Zhou, Weiming Wang, Jieming Qu

{"title":"A pilot study on Paxlovid therapy for hemodialysis patients with severe acute respiratory syndrome coronavirus 2 infections.","authors":"Xu Hao, Zhiyao Bao, Ranran Dai, Xiaojing Wu, Xin Li, Muyin Zhang, Hao Li, Lili Xu, Panpan Qiao, Xuefei Liu, Weiting Hu, Ze Zhang, Jie Fang, Min Zhou, Weiming Wang, Jieming Qu","doi":"10.1007/s11684-023-1011-0","DOIUrl":"10.1007/s11684-023-1011-0","url":null,"abstract":"We aimed to investigate the safety and efficacy of nirmatrelvir/ritonavir (Paxlovid) therapy for hemodialysis-dependent patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Thirteen hemodialysis patients infected with the Omicron variant of SARS-CoV-2 from April 3 to May 30, 2022, were recruited. Laboratory parameters and chest CT (computed tomography) imaging were analyzed. The treatment group included six patients who received 150 mg/100 mg of Paxlovid orally once daily for 5 days, whereas the control group included seven patients who received basic treatment. No serious adverse reactions or safety events were recorded. Four control patients progressed to moderate disease, and none in the treatment group showed progression of chest CT findings (P < 0.05). Paxlovid therapy tended toward early viral clearance and low viral load on Day 8. Moreover, 83.3% of the patients in the treatment group and 57.1% of the patients in the control group turned negative within 22 days. In the Paxlovid treatment group, we found significantly increased levels of lymphocytes (P=0.03) and eosinophils (P=0.02) and decreased levels of D-dimer on Day 8 compared with those on Day 1. Paxlovid therapy showed a potential therapeutic effect with good tolerance in hemodialysis patients. The optimal dose and effectiveness evaluation must be further investigated in a largeer cohort.","PeriodicalId":12558,"journal":{"name":"Frontiers of Medicine","volume":" ","pages":"169-179"},"PeriodicalIF":8.1,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136397186","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association of TRMT2B gene variants with juvenile amyotrophic lateral sclerosis. TRMT2B基因变异与幼年肌萎缩侧索硬化症的相关性。

IF 8.1 3区医学

Frontiers of Medicine Pub Date : 2024-02-01 Epub Date: 2023-10-24 DOI: 10.1007/s11684-023-1005-y

Yanling Liu, Xi He, Yanchun Yuan, Bin Li, Zhen Liu, Wanzhen Li, Kaixuan Li, Shuo Tan, Quan Zhu, Zhengyan Tang, Feng Han, Ziqiang Wu, Lu Shen, Hong Jiang, Beisha Tang, Jian Qiu, Zhengmao Hu, Junling Wang

{"title":"Association of TRMT2B gene variants with juvenile amyotrophic lateral sclerosis.","authors":"Yanling Liu, Xi He, Yanchun Yuan, Bin Li, Zhen Liu, Wanzhen Li, Kaixuan Li, Shuo Tan, Quan Zhu, Zhengyan Tang, Feng Han, Ziqiang Wu, Lu Shen, Hong Jiang, Beisha Tang, Jian Qiu, Zhengmao Hu, Junling Wang","doi":"10.1007/s11684-023-1005-y","DOIUrl":"10.1007/s11684-023-1005-y","url":null,"abstract":"Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by progressive degeneration of motor neurons, and it demonstrates high clinical heterogeneity and complex genetic architecture. A variation within TRMT2B (c.1356G>T; p.K452N) was identified to be associated with ALS in a family comprising two patients with juvenile ALS (JALS). Two missense variations and one splicing variation were identified in 10 patients with ALS in a cohort with 910 patients with ALS, and three more variants were identified in a public ALS database including 3317 patients with ALS. A decreased number of mitochondria, swollen mitochondria, lower expression of ND1, decreased mitochondrial complex I activities, lower mitochondrial aerobic respiration, and a high level of ROS were observed functionally in patient-originated lymphoblastoid cell lines and TRMT2B interfering HEK293 cells. Further, TRMT2B variations overexpression cells also displayed decreased ND1. In conclusion, a novel JALS-associated gene called TRMT2B was identified, thus broadening the clinical and genetic spectrum of ALS.","PeriodicalId":12558,"journal":{"name":"Frontiers of Medicine","volume":" ","pages":"68-80"},"PeriodicalIF":8.1,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49689833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Panoramic variation analysis of a family with neurodevelopmental disorders caused by biallelic loss-of-function variants in TMEM141, DDHD2, and LHFPL5. TMEM141、DDHD2和LHFPL5双等位基因功能缺失变异引起的神经发育障碍家族的全景变异分析。

IF 8.1 3区医学

Frontiers of Medicine Pub Date : 2024-02-01 Epub Date: 2023-10-14 DOI: 10.1007/s11684-023-1006-x

Liwei Sun, Xueting Yang, Amjad Khan, Xue Yu, Han Zhang, Shirui Han, Xiaerbati Habulieti, Yang Sun, Rongrong Wang, Xue Zhang

{"title":"Panoramic variation analysis of a family with neurodevelopmental disorders caused by biallelic loss-of-function variants in TMEM141, DDHD2, and LHFPL5.","authors":"Liwei Sun, Xueting Yang, Amjad Khan, Xue Yu, Han Zhang, Shirui Han, Xiaerbati Habulieti, Yang Sun, Rongrong Wang, Xue Zhang","doi":"10.1007/s11684-023-1006-x","DOIUrl":"10.1007/s11684-023-1006-x","url":null,"abstract":"Highly clinical and genetic heterogeneity of neurodevelopmental disorders presents a major challenge in clinical genetics and medicine. Panoramic variation analysis is imperative to analyze the disease phenotypes resulting from multilocus genomic variation. Here, a Pakistani family with parental consanguinity was presented, characterized with severe intellectual disability (ID), spastic paraplegia, and deafness. Homozygosity mapping, integrated single nucleotide polymorphism (SNP) array, whole-exome sequencing, and whole-genome sequencing were performed, and homozygous variants in TMEM141 (c.270G>A, p.Trp90*), DDHD2 (c.411+767_c.1249-327del), and LHFPL5 (c.250delC, p.Leu84*) were identified. A Tmem141p.Trp90*/p.Trp90* mouse model was generated. Behavioral studies showed impairments in learning ability and motor coordination. Brain slice electrophysiology and Golgi staining demonstrated deficient synaptic plasticity in hippocampal neurons and abnormal dendritic branching in cerebellar Purkinje cells. Transmission electron microscopy showed abnormal mitochondrial morphology. Furthermore, studies on a human in vitro neuronal model (SH-SY5Y cells) with stable shRNA-mediated knockdown of TMEM141 showed deleterious effect on bioenergetic function, possibly explaining the pathogenesis of replicated phenotypes in the cross-species mouse model. Conclusively, panoramic variation analysis revealed that multilocus genomic variations of TMEM141, DDHD2, and LHFPL5 together caused variable phenotypes in patient. Notably, the biallelic loss-of-function variants of TMEM141 were responsible for syndromic ID.","PeriodicalId":12558,"journal":{"name":"Frontiers of Medicine","volume":" ","pages":"81-97"},"PeriodicalIF":8.1,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41197913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effects and mechanisms of acupuncture on women related health. 针灸对妇女健康的影响和机制。

IF 8.1 3区医学

Frontiers of Medicine Pub Date : 2024-02-01 Epub Date: 2023-12-27 DOI: 10.1007/s11684-023-1051-5

Huichao Qin, Jiaxing Feng, Xiaoke Wu

{"title":"Effects and mechanisms of acupuncture on women related health.","authors":"Huichao Qin, Jiaxing Feng, Xiaoke Wu","doi":"10.1007/s11684-023-1051-5","DOIUrl":"10.1007/s11684-023-1051-5","url":null,"abstract":"Globally, public health interventions have resulted in a 30-year increase in women's life expectancy. However, women's health has not increased when socioeconomic status is ignored. Women's health has become a major public health concern, for those women from developing countries are still struggling with infectious and labor-related diseases, and their counterparts in developed countries are suffering from physical and psychological disorders. In recent years, complementary and alternative medicine has attracted wide attentions with regards to maintaining women's health. Acupuncture, a crucial component of traditional Chinese medicine, has been used to treat many obstetric and gynecological diseases for thousands of years due to its analgesic and anti-inflammatory effects and its effects on stimulating the sympathetic/parasympathetic nervous system. To fully understand the mechanism through which acupuncture exerts its effects in these diseases would significantly extend the list of available interventions and would allow for more reasonable advice to be given to general practitioners. Therefore, by searching PubMed and CNKI regarding the use of acupuncture in treating obstetric and gynecological diseases, we aimed to summarize the proven evidence of using acupuncture in maintaining women's health by considering both its effectiveness and the underlying mechanisms behind its effects.","PeriodicalId":12558,"journal":{"name":"Frontiers of Medicine","volume":" ","pages":"46-67"},"PeriodicalIF":8.1,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139048622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Trajectory of COVID-19 response and management strategy in China: scientific rationale driven strategy adjustments. 中国 COVID-19 应对和管理战略的轨迹：科学依据驱动战略调整。

IF 3.9 3区医学

Frontiers of Medicine Pub Date : 2024-02-01 Epub Date: 2024-04-02 DOI: 10.1007/s11684-024-1074-6

Zeyu Zhang, Yue Yan, Lina Zhao, Yizhou Bian, Ning Zhao, You Wu, Dahai Zhao, Zongjiu Zhang

{"title":"Trajectory of COVID-19 response and management strategy in China: scientific rationale driven strategy adjustments.","authors":"Zeyu Zhang, Yue Yan, Lina Zhao, Yizhou Bian, Ning Zhao, You Wu, Dahai Zhao, Zongjiu Zhang","doi":"10.1007/s11684-024-1074-6","DOIUrl":"10.1007/s11684-024-1074-6","url":null,"abstract":"The pneumonia caused by novel coronavirus SARS-CoV-2 infection in early December 2019, which was later named coronavirus disease 2019 (COVID-19) by the World Health Organization (WHO), rapidly spread across the world. China has made extraordinary efforts to this unprecedented pandemic, put its response and control at a very high level of infectious disease management (Category B but with measures for Category A), given top priority to the people and their lives, and balanced the pandemic control and socio-economic development. After more than three years' fighting against this disease, China downgraded the management of COVID-19 to Category B infectious disease on January 8, 2023 and the WHO declared the end of public health emergency on May 5, 2023. However, the ending of pandemic does not mean that the disease is no longer a health threat. Experiences against COVID-19 from China and the whole world should be learned to prepare well for the future public health emergencies. This article gives a systematic review of the trajectory of COVID-19 development in China, summarizes the critical policy arrangements and provides evidence for the adjustment during policy making process, so as to share experiences with international community and contribute to the global health for all humanity.","PeriodicalId":12558,"journal":{"name":"Frontiers of Medicine","volume":" ","pages":"19-30"},"PeriodicalIF":3.9,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140335303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pathogen evolution, prevention/control strategy and clinical features of COVID-19: experiences from China COVID-19 的病原体演变、预防/控制策略和临床特征：中国的经验

IF 8.1 3区医学

Frontiers of Medicine Pub Date : 2023-12-29 DOI: 10.1007/s11684-023-1043-5

引用次数: 0

Multi-omics joint analysis revealed the metabolic profile of retroperitoneal liposarcoma 多组学联合分析揭示腹膜后脂肪肉瘤的代谢特征

IF 8.1 3区医学

Frontiers of Medicine Pub Date : 2023-12-29 DOI: 10.1007/s11684-023-1020-z

Fu’an Xie, Yujia Niu, Lanlan Lian, Yue Wang, Aobo Zhuang, Guangting Yan, Yantao Ren, Xiaobing Chen, Mengmeng Xiao, Xi Li, Zhe Xi, Gen Zhang, Dongmei Qin, Kunrong Yang, Zhigang Zheng, Quan Zhang, Xiaogang Xia, Peng Li, Lingwei Gu, Ting Wu, Chenghua Luo, Shu-Hai Lin, Wengang Li

{"title":"Multi-omics joint analysis revealed the metabolic profile of retroperitoneal liposarcoma","authors":"Fu’an Xie, Yujia Niu, Lanlan Lian, Yue Wang, Aobo Zhuang, Guangting Yan, Yantao Ren, Xiaobing Chen, Mengmeng Xiao, Xi Li, Zhe Xi, Gen Zhang, Dongmei Qin, Kunrong Yang, Zhigang Zheng, Quan Zhang, Xiaogang Xia, Peng Li, Lingwei Gu, Ting Wu, Chenghua Luo, Shu-Hai Lin, Wengang Li","doi":"10.1007/s11684-023-1020-z","DOIUrl":"https://doi.org/10.1007/s11684-023-1020-z","url":null,"abstract":"Retroperitoneal liposarcoma (RLPS) is the main subtype of retroperitoneal soft sarcoma (RSTS) and has a poor prognosis and few treatment options, except for surgery. The proteomic and metabolic profiles of RLPS have remained unclear. The aim of our study was to reveal the metabolic profile of RLPS. Here, we performed proteomic analysis (n = 10), metabolomic analysis (n = 51), and lipidomic analysis (n = 50) of retroperitoneal dedifferentiated liposarcoma (RDDLPS) and retroperitoneal well-differentiated liposarcoma (RWDLPS) tissue and paired adjacent adipose tissue obtained during surgery. Data analysis mainly revealed that glycolysis, purine metabolism, pyrimidine metabolism and phospholipid formation were upregulated in both RDDLPS and RWDLPS tissue compared with the adjacent adipose tissue, whereas the tricarboxylic acid (TCA) cycle, lipid absorption and synthesis, fatty acid degradation and biosynthesis, as well as glycine, serine, and threonine metabolism were downregulated. Of particular importance, the glycolytic inhibitor 2-deoxy-D-glucose and pentose phosphate pathway (PPP) inhibitor RRX-001 significantly promoted the antitumor effects of the MDM2 inhibitor RG7112 and CDK4 inhibitor abemaciclib. Our study not only describes the metabolic profiles of RDDLPS and RWDLPS, but also offers potential therapeutic targets and strategies for RLPS.","PeriodicalId":12558,"journal":{"name":"Frontiers of Medicine","volume":"35 1","pages":""},"PeriodicalIF":8.1,"publicationDate":"2023-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139071690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Practice and principle of traditional Chinese medicine for the prevention and treatment of COVID-19 中药预防和治疗COVID-19的实践与原理

IF 8.1 3区医学

Frontiers of Medicine Pub Date : 2023-12-29 DOI: 10.1007/s11684-023-1040-8

Linhua Zhao, Chuanxi Tian, Yingying Yang, Huifang Guan, Yu Wei, Yuxin Zhang, Xiaomin Kang, Ling Zhou, Qingwei Li, Jing Ma, Li Wan, Yujiao Zheng, Xiaolin Tong

{"title":"Practice and principle of traditional Chinese medicine for the prevention and treatment of COVID-19","authors":"Linhua Zhao, Chuanxi Tian, Yingying Yang, Huifang Guan, Yu Wei, Yuxin Zhang, Xiaomin Kang, Ling Zhou, Qingwei Li, Jing Ma, Li Wan, Yujiao Zheng, Xiaolin Tong","doi":"10.1007/s11684-023-1040-8","DOIUrl":"https://doi.org/10.1007/s11684-023-1040-8","url":null,"abstract":"Traditional Chinese medicine (TCM) has played an important role in the prevention and treatment of Coronavirus disease 2019 (COVID-19) epidemic in China. The integration of Chinese and Western medicine is an important feature of Chinese COVID-19 prevention and treatment. According to a series of evidence-based studies, TCM can reduce the infection rate of severe acute respiratory syndrome coronavirus 2 in high-risk groups. For patients with mild and moderate forms of COVID-19, TCM can relieve the related signs and symptoms, shorten the period of nucleic-acid negative conversion, and reduce conversion rate to the severe form of the disease. For COVID-19 patients with severe and critical illnesses, TCM can improve inflammatory indicators and blood oxygen saturation, shorten the hospital stay, and reduce the mortality rate. During recovery, TCM can improve patients’ symptoms, promote organ function recovery, boost the quality of patients’ life, and reduce the nucleic-acid repositive conversion rate. A series of mechanism research studies revealed that capability of TCM to treat COVID-19 through antiviral and anti-inflammatory effects, immune regulation, and protection of organ function via a multicomponent, multitarget, and multipathway approach.","PeriodicalId":12558,"journal":{"name":"Frontiers of Medicine","volume":"21 1","pages":""},"PeriodicalIF":8.1,"publicationDate":"2023-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139071750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cytokine storm and translating IL-6 biology into effective treatments for COVID-19 细胞因子风暴和将 IL-6 生物学转化为 COVID-19 的有效疗法

IF 8.1 3区医学

Frontiers of Medicine Pub Date : 2023-12-29 DOI: 10.1007/s11684-023-1044-4

Tiantian Li, Dongsheng Wang, Haiming Wei, Xiaoling Xu

引用次数: 0

Decitabine induces IRF7-mediated immune responses in p53-mutated triple-negative breast cancer: a clinical and translational study 地西他滨诱导 p53 突变的三阴性乳腺癌患者产生 IRF7 介导的免疫反应：一项临床和转化研究

IF 8.1 3区医学

Frontiers of Medicine Pub Date : 2023-12-29 DOI: 10.1007/s11684-023-1016-8

{"title":"Decitabine induces IRF7-mediated immune responses in p53-mutated triple-negative breast cancer: a clinical and translational study","authors":"","doi":"10.1007/s11684-023-1016-8","DOIUrl":"https://doi.org/10.1007/s11684-023-1016-8","url":null,"abstract":"<h3>Abstract</h3> p53 is mutated in half of cancer cases. However, no p53-targeting drugs have been approved. Here, we reposition decitabine for triple-negative breast cancer (TNBC), a subtype with frequent p53 mutations and extremely poor prognosis. In a retrospective study on tissue microarrays with 132 TNBC cases, DNMT1 overexpression was associated with p53 mutations (P = 0.037) and poor overall survival (OS) (P = 0.010). In a prospective DEciTabinE and Carboplatin in TNBC (DETECT) trial (NCT03295552), decitabine with carboplatin produced an objective response rate (ORR) of 42% in 12 patients with stage IV TNBC. Among the 9 trialed patients with available TP53 sequencing results, the 6 patients with p53 mutations had higher ORR (3/6 vs. 0/3) and better OS (16.0 vs. 4.0 months) than the patients with wild-type p53. In a mechanistic study, isogenic TNBC cell lines harboring DETECT-derived p53 mutations exhibited higher DNMT1 expression and decitabine sensitivity than the cell line with wild-type p53. In the DETECT trial, decitabine induced strong immune responses featuring the striking upregulation of the innate immune player IRF7 in the p53-mutated TNBC cell line (upregulation by 16-fold) and the most responsive patient with TNBC. Our integrative studies reveal the potential of repurposing decitabine for the treatment of p53-mutated TNBC and suggest IRF7 as a potential biomarker for decitabine-based treatments.","PeriodicalId":12558,"journal":{"name":"Frontiers of Medicine","volume":"35 1","pages":""},"PeriodicalIF":8.1,"publicationDate":"2023-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139071809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0